SFNM NE Series: Therapies for neonatal encephalopathy: Targeting the latent, secondary and tertiary phases of evolving brain injury


Practice Points: 

 

  • Assessment of therapies across a range of animal models, with careful safety and pharmacokinetic studies, is vital before clinical translation.

 

  • Clinical neuroprotection trials in neonates with NE need careful planning, with adequate power and pharmacokinetic information built into the protocols.

 

  • Determination of optimal dose and timing of each agent will be important as we move into the era of therapeutic cocktails for optimizing outcomes.

 

  • The use of MRI and sequences such as MRS as a surrogate outcome measure will speed up the assessment of efficacy of potential therapies and thus accelerate clinical translation.

 

PubMed Link

To view the full text and an associated presentation, become a NBS member here

Become a member of the Newborn Brain Society today!